Abstract: An information creation apparatus includes a processor configured to, in a case where priorities of power supply are set to power supply targets, set upper limits of power storage remaining amounts of the power supply targets such that the upper limit of the power storage remaining amount of a power supply target with a lower priority is set to a value larger than a reference value.

Abstract: The present disclosure provides hNGAL muteins that bind CGRP and can be used in various application including pharmaceutical applications, for example, migraine. The present disclosure also concerns methods of making one or more muteins described herein as well as compositions and combinations comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions and combinations comprising one or more of such muteins.

Abstract: The present disclosure provides hNGAL muteins that bind CGRP and can be used in various application including pharmaceutical applications, for example, migraine. The present disclosure also concerns methods of making one or more muteins described herein as well as compositions and combinations comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules.

Abstract: The present disclosure provides hNGAL muteins that bind CGRP and can be used in various application including pharmaceutical applications, for example, migraine. The present disclosure also concerns methods of making one or more muteins described herein as well as compositions and combinations comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions and combinations comprising one or more of such muteins.

Abstract: The present disclosure provides hNGAL muteins that bind CGRP and can be used in various application including pharmaceutical applications, for example, migraine. The present disclosure also concerns methods of making one or more muteins described herein as well as compositions and combinations comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules.

Abstract: It is intended to provide a therapeutic agent and/or a preventive agent for a respiratory disease or a therapeutic agent and/or a preventive agent for a sodium channel associated disease.

Abstract: It is intended to provide a therapeutic agent and/or a preventive agent for a respiratory disease or a therapeutic agent and/or a preventive agent for a sodium channel associated disease.

Abstract: It is an aim to provide a tip unit for a liquid applicator and a liquid applicator that make written (applied) lines to change in thickness and give excellent durability. A tip unit used for a liquid applicator includes a ball house having an opening at its distal end and an introduction channel for application liquid in communication with the ball house, wherein the ball house holds therein at least two balls having a leading ball and an adjacent ball next to the leading ball, the balls being serially lined in an axial direction of the tip unit, the leading ball being partly exposed outside from the opening, and the leading ball being softer than the adjacent ball.

Abstract: It is an aim to provide a tip unit for a liquid applicator and a liquid applicator that make written (applied) lines to change in thickness and give excellent durability. A tip unit used for a liquid applicator includes a ball house having an opening at its distal end and an introduction channel for application liquid in communication with the ball house, wherein the ball house holds therein at least two balls having a leading ball and an adjacent ball next to the leading ball, the balls being serially lined in an axial direction of the tip unit, the leading ball being partly exposed outside from the opening, and the leading ball being softer than the adjacent ball.

Abstract: A plant which expresses a large amount of ubiquinone-10 and a method for producing ubiquinone-10 using the plant are provided. A dietary supplement, a food and a food additive which contains ubiquinone-10 produced by the plant or the method are provided. The plant is produced by transformation using an expression cassette in which a decaprenyl diphosphate synthase gene is operatively linked with a mitochondrial targeting sequence.

Abstract: A plant which expresses a large amount of ubiquinone-10 and a method for producing ubiquinone-10 using the plant are provided. A dietary supplement, a food and a food additive which contains ubiquinone-10 produced by the plant or the method are provided. The plant is produced by transformation using an expression cassette in which a decaprenyl diphosphate synthase gene is operatively linked with a mitochondrial targeting sequence.